“We are deeply convinced that the synergies existing between the two companies, which have over time had the chance to get to know each other, and which are further reinforced through this acquisition, will lead to the landmark establishment of a pole of excellence in the Italian industry of probiotics for human and animal health,” said Martino Verga, Sacco CEO.
“This will also undoubtedly favor research, development and innovation in the production and improvement of products for the well-being of consumers. Another shared fundamental pillar for both companies, which paves the ground for a fructuous cooperation, is the cardinal importance both assign to human capital for the achievement of their core goals.”
Maria Cristina Verdenelli, president and founding partner of Synbiotec, said, “We are thrilled to be able to share our probiotic research experience with a large international group like Sacco. The strength of its history and its global presence will allow us to explore together new applications for the probiotic market with the shared intention of improving the health and well-being of consumers. The participation of the Sacco group in Synbiotec is a great opportunity for our company, and I am sure it will help us grow and further establish ourselves in the market.”